ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO716

Betaine Supplementation Ameliorates Renal Disease Severity in Experimental ADPKD

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic

Authors

  • Tug, Ali Y., Mayo Clinic, Rochester, Minnesota, United States
  • Zhang, Song, Mayo Clinic, Rochester, Minnesota, United States
  • Vuckovic, Ivan, Mayo Clinic, Rochester, Minnesota, United States
  • Arroyo, Jennifer, Mayo Clinic, Rochester, Minnesota, United States
  • Eirin, Alfonso, Mayo Clinic, Rochester, Minnesota, United States
  • Lerman, Lilach O., Mayo Clinic, Rochester, Minnesota, United States
  • Harris, Peter C., Mayo Clinic, Rochester, Minnesota, United States
  • Torres, Vicente E., Mayo Clinic, Rochester, Minnesota, United States
  • Irazabal, Maria V., Mayo Clinic, Rochester, Minnesota, United States
Background

We have recently shown that kidney tissue levels of the methyl donor betaine and betaine dependent remethylation are lower in ADPKD, and correlate with disease severity. However, the effects of betaine supplementation have not been explored in ADPKD. We hypothesized that chronic betaine supplementation would increase renal betaine concentration and ameliorate disease progression in murine ADPKD.

Methods

One month old Pkd1 RC/RC mice were divided into three groups and started treatment with regular water or regular water supplemented with 1 or 2% betaine for 5 months (n=16 per group). All mice were euthanized at 6 months of age, and kidneys were harvested. Cystic index was determined from histological sections. 1H-NMR-based metabolomics analysis was performed from kidney tissue, urine and plasma samples.

Results

One and 2% betaine supplementation increased plasma and tissue betaine concentrations (p<0.001), reduced kidney/body weight to 1.82 and 1.85 vs 2.25 (p<0.01), and cystic index to 11.1 and 9.4 vs 21.1 (p<0.01) (Fig. 1). Tissue betaine concentrations correlated inversely with kidney/body weight (R2=0.386, p<0.01). Metabolomics analysis from tissue and plasma identified significant differences in mitochondrial fatty acid oxidation and TCA cycle pathways among the groups.

Conclusion

Chronic betaine supplementation ameliorates disease severity in murine ADPKD possibly through improving mitochondrial function. These observations may represent a promising intervention from early stages of the disease.

Funding

  • NIDDK Support